JP2011516510A5 - - Google Patents

Download PDF

Info

Publication number
JP2011516510A5
JP2011516510A5 JP2011503353A JP2011503353A JP2011516510A5 JP 2011516510 A5 JP2011516510 A5 JP 2011516510A5 JP 2011503353 A JP2011503353 A JP 2011503353A JP 2011503353 A JP2011503353 A JP 2011503353A JP 2011516510 A5 JP2011516510 A5 JP 2011516510A5
Authority
JP
Japan
Prior art keywords
hydroxy
pyridin
thieno
dihydro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011503353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516510A (ja
JP5592348B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/001937 external-priority patent/WO2009124636A1/en
Publication of JP2011516510A publication Critical patent/JP2011516510A/ja
Publication of JP2011516510A5 publication Critical patent/JP2011516510A5/ja
Application granted granted Critical
Publication of JP5592348B2 publication Critical patent/JP5592348B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011503353A 2008-04-11 2009-03-17 Ampにより活性化されたプロテインキナーゼ(ampk)アクチベーターとしてのチエノピリドン誘導体 Expired - Fee Related JP5592348B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08290364.2 2008-04-11
EP08290364 2008-04-11
PCT/EP2009/001937 WO2009124636A1 (en) 2008-04-11 2009-03-17 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Publications (3)

Publication Number Publication Date
JP2011516510A JP2011516510A (ja) 2011-05-26
JP2011516510A5 true JP2011516510A5 (https=) 2012-05-17
JP5592348B2 JP5592348B2 (ja) 2014-09-17

Family

ID=40671017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011503353A Expired - Fee Related JP5592348B2 (ja) 2008-04-11 2009-03-17 Ampにより活性化されたプロテインキナーゼ(ampk)アクチベーターとしてのチエノピリドン誘導体

Country Status (25)

Country Link
US (1) US8563729B2 (https=)
EP (1) EP2262500B1 (https=)
JP (1) JP5592348B2 (https=)
KR (1) KR101630466B1 (https=)
CN (1) CN101998853B (https=)
AU (1) AU2009235784B2 (https=)
BR (1) BRPI0910439B8 (https=)
CA (1) CA2721025C (https=)
CO (1) CO6300954A2 (https=)
DK (1) DK2262500T3 (https=)
EA (1) EA017756B1 (https=)
EC (1) ECSP10010599A (https=)
ES (1) ES2584278T3 (https=)
HR (1) HRP20160907T1 (https=)
HU (1) HUE027857T2 (https=)
IL (1) IL208067A (https=)
MX (1) MX2010011047A (https=)
MY (1) MY155836A (https=)
NZ (1) NZ589136A (https=)
PL (1) PL2262500T3 (https=)
PT (1) PT2262500T (https=)
SI (1) SI2262500T1 (https=)
UA (1) UA103321C2 (https=)
WO (1) WO2009124636A1 (https=)
ZA (1) ZA201008050B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2280952T3 (da) * 2008-05-05 2012-07-23 Merck Patent Gmbh Thienopyridinonderivater som amp-aktiverede proteinkinase(ampk)aktivatorer
CA2784553C (en) * 2009-12-29 2014-08-19 Poxel Thieno [2,3-b] pyridinedione activators of ampk and therapeutic uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130085169A1 (en) 2010-04-02 2013-04-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5990170B2 (ja) * 2010-09-01 2016-09-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 除草活性を有するケトスルタム類及びジケトピリジン類
CA2830706A1 (en) * 2011-03-07 2012-09-13 Glaxosmithkline Llc Quinolinone derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
US9827222B2 (en) 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
US10143703B2 (en) 2014-01-02 2018-12-04 Massachusetts Eye And Ear Infirmary Treating ocular neovascularization
CN104892569A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 末端取代的硝苯六甲苯黄原酸酯类的化合物、制备方法及用途
CN104945370A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 含卤代噻吩和硝苯六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104892568A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和腈基苯结构的黄原酸酯类化合物、其制备方法及用途
CN105037321A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环的黄原酸酯类的ampk激活剂、制备方法及用途
CN104945369A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和硝基苯结构的黄原酸酯类化合物、其制备方法及用途
CN105037322A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环和烷氧苯结构的黄原酸酯类化合物、其制备方法及用途
CN104926757A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 含烷氧苯基的双酰基苄胺类ampk激活剂、其制备方法及用途
CN104926755A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 硝苯双酰基苄胺类ampk激活剂、其制备方法及用途
CN105001181A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一类双酰基苄胺类的ampk激活剂、其制备方法及用途
CN105001194A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一种含氨基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104945371A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含腈基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104926756A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 一类含腈基苯的双酰基苄胺类化合物、其制备方法及用途
CN105037296A (zh) * 2015-06-24 2015-11-11 佛山市赛维斯医药科技有限公司 一类卤代苯双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104945372A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含二硝基以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
RS61919B1 (sr) 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
WO2017055925A2 (en) 2015-09-30 2017-04-06 Instituto De Medicina Molecular Methods for attenuating parasite virulence
WO2018002215A1 (en) 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
WO2020099678A1 (en) * 2018-11-16 2020-05-22 Poxel Monohydrate potassium salt of a thienopyridone derivative and its preparation process
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
KR20220160030A (ko) 2020-03-26 2022-12-05 폭셀 부신백색질형성장애증 또는 부신척수신경병증의 치료에 있어서의 티에노피리돈 유도체의 용도
MX2022012350A (es) * 2020-04-02 2022-10-27 Poxel Uso de un derivado de tienopiridona en el tratamiento de poliquistosis renal autosomica dominante (adpkd).
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
JP2024540522A (ja) 2021-11-19 2024-10-31 ザ・ブロード・インスティテュート・インコーポレイテッド キナーゼを標的結合部分で標識するための二官能性キメラ分子及びその使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626418B2 (en) 1989-05-16 1992-07-30 Merrell Pharmaceuticals Inc. Excitatory amino acid antagonists
DE4444815A1 (de) 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
MX2010008376A (es) 2008-02-04 2011-02-22 Mercury Therapeutics Inc Moduladores ampk.

Similar Documents

Publication Publication Date Title
JP2011516510A5 (https=)
HRP20160907T1 (hr) Derivati tienopiridona kao aktivatori amp-aktivirane protein kinaze (ampk)
JP2011519876A5 (https=)
HRP20120549T1 (hr) Derivati tienopiridona kao amp aktivirani aktivatori protein kinaze ampk
CA2473591C (en) 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
JP2016196492A5 (https=)
RU2007132448A (ru) Производные спирокеталей и их применение в качестве лекарственного средства против диабета
HRP20170246T4 (hr) Režim doziranja za selektivni agonist s1p1-receptora
JP2014518884A5 (https=)
JP5965484B2 (ja) ジフルオロメチレン化合物
JP2007519753A5 (https=)
JP2005514432A5 (https=)
JP2015524450A5 (https=)
JP2015510894A5 (https=)
CA2914620A1 (en) Heterocyclic derivatives and use thereof
TW200304814A (en) Bicyclic heterocycles for the treatment of diabetes and other diseases
CN110386941A (zh) Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗
AU2014241390A1 (en) GPR120 agonists for the treatment of type II diabetes
AU2020276005B2 (en) 3-aryloxyl-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof
WO2020191501A1 (en) Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders
CA2577879A1 (en) Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i.epsilon.
AU2015281799B2 (en) Enzyme interacting agents
KR20140064827A (ko) 신규한 에스트로겐 수용체 리간드
JP2012500232A5 (https=)
KR100888093B1 (ko) 약제학적 활성 화합물 및 이의 사용 방법